Asunto(s)
COVID-19 , Nefrosis Lipoidea , Síndrome Nefrótico , Femenino , Humanos , Factores Inmunológicos , Masculino , Nefrosis Lipoidea/complicaciones , Nefrosis Lipoidea/diagnóstico , Nefrosis Lipoidea/tratamiento farmacológico , Síndrome Nefrótico/diagnóstico , Síndrome Nefrótico/tratamiento farmacológico , Recurrencia , Rituximab/uso terapéutico , Resultado del TratamientoAsunto(s)
Vacuna BNT162/efectos adversos , COVID-19/prevención & control , ChAdOx1 nCoV-19/efectos adversos , Riñón/patología , Nefrosis Lipoidea/inducido químicamente , SARS-CoV-2/inmunología , Vacunación/efectos adversos , Adulto , Biopsia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nefrosis Lipoidea/diagnósticoRESUMEN
We report a case of minimal change disease (MCD) with severe acute kidney injury (AKI) following the first injection of the ChAdOx1 nCoV-19 (AZD1222) vaccine from Oxford-AstraZeneca against coronavirus disease 2019 (COVID-19). A 71-year-old man with a history of dyslipidemia and a baseline serum creatinine of 0.7mg/dL presented with nephrotic syndrome, AKI, and severe hypertension 13 days after receiving the Oxford-AstraZeneca vaccine. Refractory hyperkalemia and hypervolemia with oligoanuria prompted initiation of hemodialysis. His serum albumin was 2.6g/dL and his urinary protein-creatinine ratio was 2,321mg/mmol. Given a high suspicion for rapidly progressive glomerulonephritis, empirical glucocorticoid treatment was initiated (3 methylprednisolone pulses followed by high-dose prednisone). A kidney biopsy showed MCD and acute tubular injury. Kidney function and proteinuria subsequently improved, and hemodialysis was discontinued 38 days after the start of therapy. This case describes de novo MCD after the Oxford-AstraZeneca vaccine. It adds to the few published case reports of MCD after the Pfizer-BioNTech COVID-19 vaccine. Further reports and studies will be needed to elucidate whether MCD is truly associated with COVID-19 vaccination.
Asunto(s)
Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/diagnóstico , Vacunas contra la COVID-19/efectos adversos , Nefrosis Lipoidea/inducido químicamente , Nefrosis Lipoidea/diagnóstico , Índice de Severidad de la Enfermedad , Lesión Renal Aguda/complicaciones , Anciano , ChAdOx1 nCoV-19 , Humanos , Masculino , Nefrosis Lipoidea/complicacionesRESUMEN
We report on the development of minimal change disease (MCD) with nephrotic syndrome and acute kidney injury (AKI), shortly after first injection of the BNT162b2 COVID-19 vaccine (Pfizer-BioNTech). A 50-year-old previously healthy man was admitted to our hospital following the appearance of peripheral edema. Ten days earlier, he had received the first injection of the vaccine. Four days after injection, he developed lower leg edema, which rapidly progressed to anasarca. On admission, serum creatinine was 2.31 mg/dL and 24-hour urinary protein excretion was 6.9 grams. As kidney function continued to decline over the next days, empirical treatment was initiated with prednisone 80 mg/d. A kidney biopsy was performed and the findings were consistent with MCD. Ten days later, kidney function began to improve, gradually returning to normal. The clinical triad of MCD, nephrotic syndrome, and AKI has been previously described under a variety of circumstances, but not following the Pfizer-BioNTech COVID-19 vaccine. The association between the vaccination and MCD is at this time temporal and by exclusion, and by no means firmly established. We await further reports of similar cases to evaluate the true incidence of this possible vaccine side effect.